Journal Home
Search for

Volume 122, Issue 6, Pages 1082-1086 (December 2008)


View previous. 20 of 57 View next.

Omenn syndrome: Inflammation in leaky severe combined immunodeficiency

Anna Villa, MDa, Luigi D. Notarangelo, MDb, Chaim M. Roifman, MD, FRCPCcCorresponding Author Informationemail address

Received 3 September 2008; accepted 10 September 2008. published online 07 November 2008.

Omenn syndrome (OS) was reported until recently as a distinct form (phenotype and genotype) of severe combined immunodeficiency (SCID). Similar to other patients with SCID, patients with OS present early in infancy with viral or fungal pneumonitis, chronic diarrhea, and failure to thrive. Unlike typical SCID, patients with OS have enlarged lymphoid tissue, severe erythroderma, increased IgE levels, and eosinophilia. The inflammation observed in these patients is believed to be triggered by clonally expanded T cells, which are predominantly of the TH2 type. These abnormal T cells, in the absence of proper regulation by other components of the immune system, secrete a host of cytokines that promote autoimmune as well as allergic inflammation. The emergence of these T-cell clones occurs in patients with hypomorphic mutations in recombination activating gene 1 or 2, but not in patients with deleterious mutations in these enzymes which render them inactive. Recently, OS was also identified in a growing list of other leaky SCIDs with mutations in RNA component of mitochondrial RNA processing endoribonuclease, adenosine deaminase, IL-2 receptor γ, IL-7 receptor α, ARTEMIS, and DNA ligase 4. This new information revealed OS is a distinct inflammatory process that can be associated with genetically diverse leaky SCIDS.

a Istituto Tecnologie Biomediche, Consiglio Nazionale delle Ricerche, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy

b Division of Immunology, Children's Hospital Boston, Harvard Medical School, Boston, Mass

c Division of Immunology and Allergy, Hospital for Sick Children and the University of Toronto, Toronto, Ontario, Canada

Corresponding Author InformationReprint requests: Chaim M. Roifman MD, FRCPC, Division of Immunology/Allergy, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada.

 Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

PII: S0091-6749(08)01734-X

doi:10.1016/j.jaci.2008.09.037


View previous. 20 of 57 View next.